We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
pharmaceuticals: Archive
Best Income Stocks to Buy for April 25th
by Zacks Equity Research
CIB, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 25, 2024.
ASBFYNegative Net Change CIBPositive Net Change TAKNegative Net Change
pharmaceuticals
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
by Zacks Equity Research
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
BIIBPositive Net Change ANIPNegative Net Change ADMANegative Net Change SAGEPositive Net Change
biotechs earnings medical pharmaceuticals
4 Large Drug Stocks to Hold on to Amid Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
LLYNegative Net Change NVOPositive Net Change MRKNegative Net Change ABBVPositive Net Change
pharmaceuticals
Company News for Apr 24, 2024
by Zacks Equity Research
Companies in The News Are: UPS,PM,NVS,IVZ
NVSPositive Net Change UPSPositive Net Change PMNegative Net Change IVZPositive Net Change
consumer-staples pharmaceuticals transportation
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
by Ahan Chakraborty
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
SNYPositive Net Change BMYPositive Net Change MRKNegative Net Change GILDPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
by Zacks Equity Research
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
REGNPositive Net Change RHHBYNegative Net Change LLYNegative Net Change BAYRYPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
by Zacks Equity Research
KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson are part of the Zacks top Analyst Blog.
QCOMPositive Net Change JNJPositive Net Change IBKRPositive Net Change KBHNegative Net Change
communications computers finance pharmaceuticals
GSK Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSKPositive Net Change SRPTNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals vaccines
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
by Zacks Equity Research
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
SNYPositive Net Change LGNDNegative Net Change ANIPNegative Net Change ADMANegative Net Change
pharmaceuticals
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
SNYPositive Net Change AZNPositive Net Change BMRNNegative Net Change FUSNNegative Net Change
pharmaceuticals
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSPositive Net Change INCYPositive Net Change SRPTNegative Net Change CTMXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
NVSPositive Net Change RHHBYNegative Net Change MORPositive Net Change ARVNPositive Net Change
biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
by Zacks Equity Research
Novartis, American Express, ConocoPhillips, Netflix and Schlumberger are part of the Zacks top Analyst Blog.
NVSPositive Net Change SLBPositive Net Change COPNegative Net Change NFLXPositive Net Change AXPNegative Net Change
consumer-discretionary finance oil-energy pharmaceuticals
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
VRTXPositive Net Change ADMANegative Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
MRKNegative Net Change MRNAPositive Net Change NVAXPositive Net Change FATEPositive Net Change
pharmaceuticals
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
GILDPositive Net Change ONCYNo Net Change FATEPositive Net Change OMGAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
BMYPositive Net Change ONCYNo Net Change FATEPositive Net Change OMGAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Top Analyst Reports for Novartis, American Express & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
NVSPositive Net Change SLBPositive Net Change COPNegative Net Change NFLXPositive Net Change AXPNegative Net Change ETNNegative Net Change
finance oil-energy pharmaceuticals
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
SRPTNegative Net Change ABBVPositive Net Change CTMXNegative Net Change LABPNegative Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
ADMANegative Net Change FGENPositive Net Change IMVTPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
VRTXPositive Net Change ADMANegative Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
SRPTNegative Net Change VKTXNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
by Zacks Equity Research
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
BPTHNegative Net Change ADMANegative Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
RHHBYNegative Net Change LGNDNegative Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology medical pharmaceuticals
Novartis (NVS) to Report Q1 Earnings: What to Expect?
by Ekta Bagri
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
NVSPositive Net Change BMRNNegative Net Change ONCYNo Net Change FATEPositive Net Change
biotechnology earnings medical pharmaceuticals